Journal of Clinical Oncology, Vol 13, 2944-2953, Copyright © 1995 by American Society of Clinical Oncology
Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy
R Sridhara, MA Eisenberger, VJ Sinibaldi, LM Reyno and MJ Egorin
Department of Epidemiology and Preventive Medicine, University of Maryland Cancer Center, Baltimore 21201, USA.
PURPOSE: We evaluated the surrogate role of serum prostate-specific antigen
(PSA) using prospectively collected information from patients with
hormone-refractory prostate cancer (HRPC) treated with suramin. MATERIALS
AND METHODS: Data from 103 patients were analyzed using survival analysis,
exploratory analysis, and regression analysis. RESULTS: There was a
significant survival difference between groups of patients with a PSA
decrease of < or = 0% or greater than 0% (P = .018). There were no
significant overall survival differences between groups of patients with
PSA decreases less than 50% or > or = 50% and less than 75% or > or =
75%. Tree-based modeling did not define a specific threshold percentage PSA
change as a response criterion. For a response of 1-year survival,
sensitivity increased (0.91 v 0.69), but specificity decreased (0.37 v
0.62), with a 75% versus 50% PSA decrease used as classification criterion.
Differences between the area under the receiver-operating curves (ROCs)
with 50% and 75% PSA decreases as threshold values were small. For a
response of 1-year survival, attributable proportions were 0.38 and 0.68,
respectively, with 50% and 75% PSA decreases as threshold values. When
pretreatment variables were assessed by Cox proportional hazards model,
hemoglobin level was the most significant predictor of survival. When
percentage PSA change was included in the model, hemoglobin level remained
the most significant factor, but percentage PSA change was also a weak, but
statistically significant, factor. PSA was a weak, but statistically
significant, predictor of survival in Cox proportional hazards model with
PSA as a time-variant covariate. CONCLUSION: Reduction in PSA level has
weak prognostic significance with respect to survival in HRPC patients,
but, currently, PSA reduction cannot be used as a reliable response
criterion to evaluate treatment efficacy in individual patients.
Prospective, randomized studies, including prospective measurement of other
indices related to symptomatic clinical benefits, are required.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
D. R. Berthold, G. R. Pond, M. Roessner, R. de Wit, M. Eisenberger, a. I. F. Tannock, and on behalf of the TAX-327 investigators
Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study
Clin. Cancer Res.,
May 1, 2008;
14(9):
2763 - 2767.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Armstrong, E. Garrett-Mayer, Y.-C. Ou Yang, M. A. Carducci, I. Tannock, R. de Wit, and M. Eisenberger
Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer
J. Clin. Oncol.,
September 1, 2007;
25(25):
3965 - 3970.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Collette, T. Burzykowski, K. J. Carroll, D. Newling, T. Morris, and F. H. Schroder
Is Prostate-Specific Antigen a Valid Surrogate End Point for Survival in Hormonally Treated Patients With Metastatic Prostate Cancer? Joint Research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals
J. Clin. Oncol.,
September 1, 2005;
23(25):
6139 - 6148.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. I. Scher, M. J. Morris, W. K. Kelly, L. H. Schwartz, and G. Heller
Prostate Cancer Clinical Trial End Points: "RECIST"ing a Step Backwards
Clin. Cancer Res.,
July 15, 2005;
11(14):
5223 - 5232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Oudard, E. Banu, P. Beuzeboc, E. Voog, L. M. Dourthe, A. C. Hardy-Bessard, C. Linassier, F. Scotte, A. Banu, Y. Coscas, et al.
Multicenter Randomized Phase II Study of Two Schedules of Docetaxel, Estramustine, and Prednisone Versus Mitoxantrone Plus Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
J. Clin. Oncol.,
May 20, 2005;
23(15):
3343 - 3351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Molenberghs, T. Burzykowski, A. Alonso, and M. Buyse
A perspective on surrogate endpoints in controlled clinical trials
Statistical Methods in Medical Research,
June 1, 2004;
13(3):
177 - 206.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. J. Ryan and E. J. Small
The Selection of Hormonal Therapy in Prostate Cancer: Who, When, and for How Long?
J Natl Compr Canc Netw,
May 1, 2004;
2(3):
261 - 268.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Halabi, E. J. Small, P. W. Kantoff, M. W. Kattan, E. B. Kaplan, N. A. Dawson, E. G. Levine, B. A. Blumenstein, and N. J. Vogelzang
Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer
J. Clin. Oncol.,
April 1, 2003;
21(7):
1232 - 1237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Smaletz, H. I. Scher, E. J. Small, D. A. Verbel, A. McMillan, K. Regan, W. K. Kelly, and M. W. Kattan
Nomogram for Overall Survival of Patients With Progressive Metastatic Prostate Cancer After Castration
J. Clin. Oncol.,
October 1, 2002;
20(19):
3972 - 3982.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Small, S. Halabi, M. J. Ratain, G. Rosner, W. Stadler, D. Palchak, E. Marshall, R. Rago, V. Hars, G. Wilding, et al.
Randomized Study of Three Different Doses of Suramin Administered With a Fixed Dosing Schedule in Patients With Advanced Prostate Cancer: Results of Intergroup 0159, Cancer and Leukemia Group B 9480
J. Clin. Oncol.,
August 15, 2002;
20(16):
3369 - 3375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Small, A. McMillan, M. Meyer, L. Chen, W. J. Slichenmyer, P. F. Lenehan, and M. Eisenberger
Serum Prostate-Specific Antigen Decline as a Marker of Clinical Outcome in Hormone-Refractory Prostate Cancer Patients: Association With Progression-Free Survival, Pain End Points, and Survival
J. Clin. Oncol.,
March 1, 2001;
19(5):
1304 - 1311.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. C. Dixon, K. B. Knopf, and W. D. Figg
The Control of Prostate-Specific Antigen Expression and Gene Regulation by Pharmacological Agents
Pharmacol. Rev.,
March 1, 2001;
53(1):
73 - 92.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Small, P. Fratesi, D. M. Reese, G. Strang, R. Laus, M. V. Peshwa, and F. H. Valone
Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells
J. Clin. Oncol.,
December 1, 2000;
18(23):
3894 - 3903.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Small, M. Meyer, M. E. Marshall, L. M. Reyno, F. J. Meyers, R. B. Natale, P. F. Lenehan, L. Chen, W. J. Slichenmyer, and M. Eisenberger
Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone
J. Clin. Oncol.,
April 7, 2000;
18(7):
1440 - 1450.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Bubley, M. Carducci, W. Dahut, N. Dawson, D. Daliani, M. Eisenberger, W. D. Figg, B. Freidlin, S. Halabi, G. Hudes, et al.
Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group
J. Clin. Oncol.,
November 1, 1999;
17(11):
3461 - 3467.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. W. Kantoff, S. Halabi, M. Conaway, J. Picus, J. Kirshner, V. Hars, D. Trump, E. P. Winer, and N. J. Vogelzang
Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
J. Clin. Oncol.,
August 1, 1999;
17(8):
2506 - 2506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. T. Vollmer, P. W. Kantoff, N. A. Dawson, and N. J. Vogelzang
A Prognostic Score for Hormone-Refractory Prostate Cancer: Analysis of Two Cancer and Leukemia Group B Studies
Clin. Cancer Res.,
April 1, 1999;
5(4):
831 - 837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. I. Scher, W. M. K. Kelly, Z.-F. Zhang, P. Ouyang, M. Sun, M. Schwartz, C. Ding, W. Wang, I. D. Horak, and A. B. Kremer
Post-therapy Serum Prostate-Specific Antigen Level and Survival in Patients With Androgen-Independent Prostate Cancer
J Natl Cancer Inst,
February 3, 1999;
91(3):
244 - 251.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
